LNK101 NCT06756035 Clinical Landscape 2026

Explore the PatSnap Life Sciences MCP marketplace

This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.

Data snapshot: 16 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.

Phase 1

Clinical phase

Terminated

Recruitment status

70

Planned enrollment

2026-12-01

Primary-completion proxy

Executive view

NCT06756035 evaluates LNK101 in Advanced Bile Duct Carcinoma. The disclosed sponsor is Context Therapeutics, Inc., the design is Interventional, and the geographic footprint is United States. The first listed primary endpoint is Determine the MTD or RD of CT-95 [Safety and Tolerability], assessed over From date of first dose of CT-95 until 28 days following the first dose..

The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.

PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.

How the MCP evidence stack was assembled

Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT06756035 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Advanced Bile Duct Carcinoma landscape. Drug & Asset MCP drug_fetch was queried for LNK101, while Company & Deal Intelligence MCP organization_fetch was queried for Context Therapeutics, Inc..

This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.

Trial landscape table

Trial	Asset / intervention	Phase / status	Sponsor	Geography	Primary endpoint	Readout proxy
NCT06756035	LNK101	Phase 1 / Terminated	Context Therapeutics, Inc.	United States	Determine the MTD or RD of CT-95 [Safety and Tolerability] From date of first dose of CT-95 until 28 days following the first do…	2026-12-01
NCT07131345	Iparomlimab/Tuvonralimab	Phase 1/2 / Not yet recruiting	Sponsor not reported	Geography not reported	ORR From enrollment to the end of treatment at 8 weeks	2026-10-31
NCT06885697	Fludarabine Phosphate	Phase 1 / Recruiting	National Cancer Institute	United States	Establish the recommended phase 2 dose (RP2D) of TNhYP218 CAR T cells based on dose-limiting toxicity (DLT) of defined… DLT assessment will occur in participants in the dose escalation coho…	2034-06-01
NCT06875076	Ivonescimab	Phase 2 / Recruiting	The First Hospital of Jilin University	China	objective response rate (ORR) From enrollment to the end of treatment at 3 months	2028-01-01
NCT06840834	Ivonescimab	Phase 2 / Recruiting	Intergroupe Francophone Cancerologie Thoracique	France	To assess the therapeutic value of the bispecific antibody anti-VEGF / anti-PD-1 ivonescimab as 2nd/3rd line treatment… 12 weeks after start of treatment.	2026-09-30

The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.

Reproduce the trial-to-asset workflow with PatSnap MCP

Protocol design and endpoint interpretation

NCT06756035 is a Phase 1, terminated study with 70 planned participants. Allocation is N/A, masking is None (Open Label), and the intervention model is Single Group Assignment.

The primary endpoint is “Determine the MTD or RD of CT-95 [Safety and Tolerability]” over “From date of first dose of CT-95 until 28 days following the first dose..” The retrieved endpoint description is: The frequency of dose-limiting toxicities (DLTs) will be analyzed along with safety and tolerability measures to determine the MTD or RD of CT-95..

Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 70 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.

No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.

Indexed readouts in the surrounding landscape

5 recent result records were selected as contextual evidence for Advanced Bile Duct Carcinoma. These records do not establish direct evidence for NCT06756035 unless the registration number matches.

First-Line Pumitamig (PD-L1 × VEGF-A bsAb) Plus Chemotherapy in Unresectable Malignant Mesothelioma: Long-Term PFS and OS

Phase 2; n=31; OS(24-month) = 25.0 % ; OS(24-month) = 50.7 % Source: https://cattendee.abstractsonline.com/meeting/21487/Session/133

Phase II Trial of Olaparib in Patients With Mesothelioma

Phase 2; n=34; ORR = 3.0 % Source: https://cattendee.abstractsonline.com/meeting/21487/Session/195

Tumour Extrinsic Regulation of Neutrophils Sensitize Mesotheliomas to AXL and PD1 Inhibition inMIST3, a Phase II Clinical Trial

Phase 2; n=21; DCR(12-week) = 46.2 % ( 29.2 - 63.8) Source: https://cattendee.abstractsonline.com/meeting/21487/Session/133

Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.

Asset and sponsor context

No exact Drug & Asset MCP profile was returned for the protocol wording “LNK101.” The report therefore avoids inferring modality, target or global development stage from the name alone.

No exact Company & Deal Intelligence profile was returned for Context Therapeutics, Inc.. Sponsor identity is retained from the trial protocol without adding unsupported corporate claims.

For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.

Development white space

Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
Sequencing white space. Clarify whether LNK101 is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.

White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.

Strategic implications and next readouts

For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.

For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.

Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.

Source trail and bottom line

Anchor trial: NCT06756035
Protocol source: https://clinicaltrials.gov/study/NCT06756035
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 16 September 2026.

LNK101 in Advanced Bile Duct Carcinoma is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Determine the MTD or RD of CT-95 [Safety and Tolerability] and 2026-12-01 the leading decision points.

Build and refresh clinical landscape reports with PatSnap MCP